Whitfield Advises Curium on Merger with Lantheus
Overview
Curium agreed to combine with Lantheus in a radiopharmaceutical transaction valued at up to approximately $8 billion, according to the source announcement.
Shareholder consideration
Lantheus holders would receive $102.50 cash per share plus non-transferable rights to potential additional payments totaling up to $12 per share.
Milestones and timetable
Additional consideration depended on commercial milestones through 2030. Closing was expected in the first half of 2027 after shareholder and regulatory approvals.
Named advisers
Rachael Coffey and Carlos Gil Rivas are among the corporate advisers credited, with separate debt finance and competition workstreams also listed.
Sources & Further Reading
Related Pages
Whitfield Advises AEVEX on Acquisition of BlackSea TechnologiesWhitfield Advises Thrive Holdings on $2 Billion FundraiseWhitfield Represents Trinity Hunt Partners on Investment in Fisher Management PartnersAustinBostonChicago
View More (19)
HoustonMiamiBay Area – San FranciscoWashington, D.C.Technology & IP TransactionsAntitrust & CompetitionGovernment ContractsCapital MarketsDebt FinanceEmployment & LaborEnergy RegulatoryEnvironmentalExecutive CompensationHealthcare & Life Sciences TransactionsInvestment FundsMergers & AcquisitionsReal AssetsReal EstateTax
